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ABSTRACT
Introduction Most cardiovascular disease (CVD)- related 
events could be prevented or substantially delayed with 
improved diet and lifestyle. Providing information on 
structural vascular disease may improve CVD risk factor 
management, but its impact on lifestyle change remains 
unclear. This study aims to determine whether providing 
visualisation and pictorial representation of structural 
vascular disease (abdominal aortic calcification (AAC)) can 
result in healthful diet and lifestyle change.
Methods and analysis This study, including men and 
women aged 60–80 years, is a 12- week, two- arm, 
multisite randomised controlled trial. At baseline, all 
participants will have AAC assessed from a lateral spine 
image captured using a bone densitometer. Participants 
will then be randomised to receive their AAC results at 
baseline (intervention group) or a usual care control group 
that will receive their results at 12 weeks. All participants 
will receive information about routinely assessed CVD risk 
factors and standardised (video) diet and lifestyle advice 
with three simple goals: (1) increase fruit and vegetable 
(FV) intake by at least one serve per day, (2) improve other 
aspects of the diet and (3) reduce sitting time and increase 
physical activity. Clinical assessments will be performed at 
baseline and 12 weeks.
Outcomes The primary outcome is a change in serum 
carotenoid concentrations as an objective measure of FV 
intake. The study design, procedures and treatment of data 
will adhere to Standard Protocol Items for Randomized 
Trials guidelines.
Ethics and dissemination Ethics approval for this study 
has been granted by the Edith Cowan University and the 
Deakin University Human Research Ethics Committees 
(Project Numbers: 20513 HODGSON and 2019-220, 
respectively). Results of this study will be published 
in peer- reviewed academic journals and presented in 
scientific meetings and conferences. Information regarding 
consent, confidentiality, access to data, ancillary and post- 
trial care and dissemination policy has been disclosed in 
the participant information form.
Trial registration number Australian New Zealand 
Clinical Trial Registry (ACTRN12618001087246).
InTROduCTIOn
Background and rationale
Cardiovascular diseases (CVDs) are the 
leading cause of death. Globally, over 30% of 
all deaths are attributable to CVDs, with the 
majority of these due to either ischemic heart 
disease (heart attack) or cerebrovascular 
disease (stroke).1 In Australia, approximately 
29% of all deaths have an underlying cause of 
CVD.2 Often heart attacks and strokes are the 
first clinical symptom of CVD with approx-
imately 31% of first events being fatal.3 
Furthermore, most survivors have substan-
tial reductions in quality of life (QoL) due to 
changes in functional capacity.
Poor lifestyle behaviours contribute to 
the majority of CVD globally; improving 
Strengths and limitations of this study
 ► To date, no studies have investigated whether pro-
viding visualisation and pictorial representation of 
structural vascular disease in the abdominal aorta 
(abdominal aortic calcification (AAC)) assessed on 
scans from bone densitometers can result in greater 
uptake and adherence to dietary and physical activ-
ity recommendations.
 ► AAC from widely available bone densitometers is a 
quick, cost- effective and reproducible method to vi-
sualise structural vascular disease.
 ► Given the advantages of the imaging modality, this 
test may be a useful tool to encourage individuals to 
make healthful lifestyle choices and general prac-
titioners to reinforce healthful lifestyle recommen-
dations and encourage initiation and adherence to 
cardiovascular medications.
 ► A limitation is that this is a short- term 12- week ran-
domised controlled trial and as such we cannot de-
termine long- term dietary and lifestyle differences 
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diet, increasing physical activity and the cessation of 
smoking can substantially reduce the burden of CVD.4 
Even modest sustained lifestyle changes, such as adding 
an extra serve of fruit and vegetable (FV) to the diet 
or reducing sitting time, can lower CVD risk.5 Growing 
evidence shows that a diet rich in FV (eg, two and five 
daily serves of fruit and vegetable, respectively), can 
lower the risk of CVD death, non- cardiovascular death 
and death from all causes.6–9
Worldwide, over 5 million deaths per year are attributed 
to diets low in FV;7 well over 10 million deaths per year 
are attributed to lifestyle, including poor diet, physical 
inactivity and smoking. Although there is an estimated 
20% lower risk of CVD comparing high to low FV intake 
(a 5% lower risk for each additional serving),6 most adults 
do not meet the minimum recommended servings for 
fruits (2 servings; ≥300 g/day) or vegetables (~5 serv-
ings; ≥375 g/day).10 11 In addition, 70%–80% of adults 
fail to engage in the recommended amount of physical 
activity.12 Improved diet and increased physical activity 
would reduce the health expenditure associated with 
chronic diseases.13 14
Current policy to prevent chronic disease is predicated 
on detection of the traditional, recognised risk factors 
such as altered blood lipids and elevated blood pres-
sure (BP). However, new non- invasive tests that strongly 
predict disease presence, development, progression 
and outcome may lead to a paradigm shift in CVD risk 
management and primary prevention of clinical disease.15 
Vascular calcification can be used to assess atherosclerotic 
vascular disease presence and burden. It can be measured 
by CT in the coronary arteries (coronary artery calcifica-
tion (CAC)) and X- ray in the abdominal aorta (abdom-
inal aortic calcification (AAC)). The presence of any 
CAC or any AAC provides a measurement of the amount 
of calcium deposited in arteries, which are the surro-
gates for atherosclerosis, strongly predict CVD events 
and substantially improve both sensitivity and specificity 
to the identification of future CVD events.16–18 Further-
more, new calcified lesions (progression) are evidence of 
active atherosclerosis likely to be related to poorer patient 
outcomes.19 These methods represent a significant 
advancement in CVD risk estimation and may be used in 
primary prevention. However, due to cost and radiation 
concerns, these tests are not used for community- based or 
routine screening. In contrast, AAC assessed from lateral 
spine images used to detect vertebral fractures from dual 
energy X- ray absorptiometry (DXA) scans, offer an alter-
native and widely available method which has ultra- low 
to negligible radiation (0.005 mSv), low cost and, conse-
quently, can be used routinely in almost all clinical 
populations.
Good evidence suggests that CAC screening improves 
medication adherence and CVD risk factor manage-
ment.20 21 However, there are limited data as to whether 
CAC screening can motivate individuals towards bene-
ficial behavioural or lifestyle changes to improve CVD 
risk.21 To date, most of the available data in this area are 
mixed21 and derived from observational studies, with only 
a few randomised controlled trials (RCTs) conducted.21
Providing individuals with visualisation and pictorial 
representation of structural vascular disease followed 
by diet and lifestyle advice could stimulate protective 
health behaviours. This approach is supported by well- 
established models of health promotion and preven-
tive behaviour.22–24 To date, no studies have investigated 
whether providing individuals with visualisation and 
pictorial representation of the presence and severity of 
advanced structural vascular disease in the abdominal 
aorta can improve both diet and physical activity, the 
primary modifiable causes of CVD. In addition, AAC 
scanning is a relatively new technique compared with 
CAC scanning. It is important to examine within an RCT 
framework the extent to which this technique can be used 
as a tool to encourage healthy behaviour change and 
monitor progression of CVD.
Objectives
The primary aim of this study is to investigate, for the first 
time, whether providing individuals with visualisation and 
pictorial representation of structural vascular disease pres-
ence and severity, assessed by widely available bone densi-
tometers, can increase objective measures of FV intake 
(serum carotenoids) after 12 weeks. Major secondary aims 
are to evaluate whether providing visualisation and pictorial 
representation of structural vascular disease will affect (1) 
adherence to other dietary recommendations (eg, sodium, 
fibre, whole grains, seeds and nuts); (2) adherence to 
physical activity and sedentary behaviour (eg, sitting time) 
recommendations; (2) CVD risk factors (such as BP, lipids 
and glucose levels) and; (4) other health- related measures 
(eg, gut health, physical function and mental health).
Trial design
This will be a 12- week, single- blind, two- arm, multisite RCT. 
The study trial complies with the Standard Protocol Items 
for Randomized Trials recommendations and guidelines for 
protocols.25 This study will run in parallel at the Royal Perth 
Hospital Medical Research Foundation, School of Medical 
and Health Sciences at Edith Cowan University (Perth site) 
and within the Institute for Physical Activity and Nutrition, 
School of Exercise and Nutrition Sciences, Melbourne 
Burwood Campus at Deakin University (Melbourne site). 
Participants will be randomised (1:1) to either be provided 
with their AAC results at baseline (intervention group) 
or delayed until 12 weeks at the end of the RCT (control 
group). Participants will be stratified according to the age 
(above or below 70 years) and sex. A detailed process eval-
uation will be performed to assess the suitability, reliability 
and implementation of all processes involved (Anokye R, 
Radavelli- Bagatini S, Bondonno CP, et al. Process evalua-
tion protocol for a multicentre, single- blind randomized 
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Figure 1 Study flow chart.
METhOdS
Participants, interventions and outcomes
Study settings
This study will be conducted in ambulant community- 
dwelling Australian men and women, aged 60–80 years, 
recruited from the general population in metropolitan 
Perth and Melbourne and surrounding areas in Australia.
Eligibility criteria
A total of 200 participants (n=100 control group; n=100 
intervention group) from Perth and Melbourne will 
be recruited from the general population via media 
advertisements and participant databases from previous 
studies. A two- step screening process will be performed. 
Eligibility will be assessed initially via a telephone 
prescreen, followed by clinical assessments. An initial 
telephone screening questionnaire will be used to deter-
mine the eligibility of potential participants based on the 
inclusion/exclusion criteria. Volunteers who are eligible 
and willing to proceed will be sent an information pack 
and a clinic assessment visit will be scheduled for further 
screening and testing.
Inclusion and exclusion criteria
Participants included will be ambulant men and women 
aged 60–80 years. Exclusion criteria are (1) Body mass 
index (BMI) ≥37 kg/m2 or BMI <18 kg/m2 or body weight 
>125 kg; (2) type 1 diabetes; (3) type 2 diabetes if greater 
than 10 years since diagnosis; (4) history of CVD events 
including ischemic heart disease, cerebrovascular disease, 
cardiomyopathy and peripheral arterial disease; (5) prior 
CAC or coronary angiograms (within the last 2 years); (6) 
use of anticoagulant therapy (warfarin); (7) those with 
significant comorbidities, such as chronic kidney disease 
(estimated glomerular filtration rate (eGFR) <30 mL/
min/1.73 m2), cancer (current) or heart failure (class 
3 and 4)26; (8) systolic BP >160 mm Hg or diastolic BP 
>100 mm Hg; (9) poor- image quality of the DXA scans 
resulting in an inability to assess the AAC and (10) those 
unable or unwilling to follow the study protocol. Eligible 
participants will be asked to sign an informed consent 
form prior to participation.
Assessments
The study flow chart is summarised in figure 1. At base-
line, all participants will attend their screening appoint-
ment and baseline assessments, which includes their AAC 
assessment from a lateral spine image captured using a 
DXA densitometer. Participants will be then randomised 
to either the control or the intervention group. Although 
all participants will have their AAC scan performed at 
baseline, only the intervention group will be provided 
visualisation and pictorial representation of their AAC at 
baseline. The control group will be provided this infor-
mation at the end of the RCT (12 weeks). The schedule 
of enrolment, interventions and assessments for the 
study is shown in table 1. We will allow 3 weeks (lead- in 
phase) for all baseline biochemistry and AAC results to 
be available, before participants can be randomised and 
attend the counselling visit. The lead- in phase will include 
the following baseline assessments: (1) DXA scan for AAC 
assessment as well as bone density (hip and spine) and 
body composition; (2) anthropometry (body weight, 
height, waist and hip circumference); (3) a fasting blood 
sample for measurement of carotenoids (markers of 
FV intake), glucose, creatinine (to estimate eGFR) and 
lipids (cholesterol, triglycerides, high- density lipopro-
tein (HDL) cholesterol); (4) urine sample for urinary 
sodium, potassium and creatinine levels; (5) saliva test for 
nitrate and nitrite concentrations; (6) clinic BP; (7) arte-
rial stiffness using pulse wave analysis (PWA); (8) physical 
activity assessed using ACTiGraph accelerometers and (9) 
physical function assessments (handgrip strength (GS), 
timed- up- and- go and gait speed). Questionnaires will be 
used to capture information on other health and lifestyle 
measures.
Baseline counselling visit
After being randomised to either the control or the inter-
vention group, all participants will receive a 30- minute 
counselling session visit (week 0), as outlined in table 2. 
An unblinded counsellor trained in the need for impar-
tiality will conduct all counselling sessions. To standardise 
counselling, all participants will watch three educational 
videos (~1, 3 and 7 min each, respectively), will receive 
a booklet with dietary and lifestyle information and will 
be provided with their baseline biochemistry (CVD risk 
factor) results. This visit will run as follows:
1. The first video will contain information on the bur-
den of CVD in Australia (from the Heart Foundation 
Australia). This will be immediately followed by a sec-
ond video containing information on blood vessel dis-
ease (atherosclerosis) and how this leads to CVD. For 
the intervention group (AAC assessed), this video will 
also include a short explanation of AAC and its link to 
risk of heart attack and stroke. The video will conclude 
by encouraging dietary and physical activity change to 
reduce the risk of a heart attack or stroke.
2. Participants will be instructed to open an envelope 
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Table 1 Study design
Enrolment Allocation






Intervention: Information on AAC x
Control: Information on AAC x
Dietary and lifestyle advice x x
Assessments
Anthropometry x x
Dual energy X- ray absorptiometry x x
Blood, urine and saliva samples x x
Blood pressure x x
Arterial stiffness x x
Physical activity x x
Physical function x x
Questionnaires x x
AAC, abdominal aortic calcification.
Table 2 Baseline counselling session chart flow
Intervention group Estimated time Control group Estimated time
Video 1: National Heart 
Foundation of Australia
1 min Video 1: National Heart 
Foundation of Australia
1 min
Video 2: information on 
cardiovascular disease and AAC
3.5 min Video 2: information on 
cardiovascular disease
3 min
Letter with visual and pictorial 
representation of their AAC scan 
results
Biochemistry and blood pressure 
results
Letter to the GP regarding the 
study
5 min Letter without AAC scan results
Biochemistry and blood 
pressure results
5 min
Video 3: dietary and lifestyle 
information
7 min Video 3: dietary and lifestyle 
information
7 min
  Further information
 ► Booklet on dietary and lifestyle 
information
 ► Frequently asked questions 
(FAQ)
5 min   Further information




Face- to- face conversation with 
investigator
5 min Face- to- face conversation with 
investigator
5 min
Postcounselling health status 
questionnaire
3 min Postcounselling health status 
questionnaire
3 min
Total time 29.5 min Total time 29 min
Information in italic represent the differences between intervention and control groups
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assessments (both groups), including glucose and lipid 
levels and blood pressure—any values outside the ref-
erence ranges will be flagged for general practitioner 
(GP) follow- up; and (2) for the intervention (AAC as-
sessed) group only, the results of their AAC scan will 
include a graphic image with a pictorial representation 
of the degree of calcification present and they will also 
be provided with an explanatory results letter for their 
GPs. Participants in both groups will be encouraged to 
share all of their results with their GP.
3. The third video will then provide dietary and lifestyle 
counselling, which will summarise usual care standard 
dietary and lifestyle advice, with recommendations 
based on the Australian Dietary Guidelines27 and the 
recommendations on physical activity for older Aus-
tralians,28 outlining three specific goals to be achieved 
and maintained (1) to increase fresh fruit intake by at 
least one serve per day (150 g/day) and increase veg-
etable intake by at least one serve per day (75 g/day); 
(2) to improve other aspects of diet such as limiting 
intakes of saturated and trans fats, salt, sugar and al-
cohol and increasing the intake of whole grains, seeds 
and nuts; and (3) to increase physical activity and re-
duce sitting time. There will also be information on 
other dietary and lifestyle recommendations including 
serving sizes, food groups and alcohol intake (standard 
drinks) based on the Australians Dietary Guidelines27 
and The Heart Foundation Australia recommenda-
tions29; and key websites that may assist participants 
to achieve desired changes. The video content will be 
compiled in a hard copy booklet with additional detail 
in relation to each of the three study goals, which will 
also be provided to participants.
4. All participants will be provided with frequently asked 
questions and will have a 5- minute face- to- face con-
versation with the investigator, who will answer any 
questions raised. Participants will be asked to answer 
a postcounselling questionnaire to assess perceived 
health status.
At 12 weeks (end of RCT), all measurements performed 
at baseline will be repeated. In addition, the counselling 
sessions will be provided to both groups with the interven-
tion group receiving the control group’s baseline counsel-
ling and vice versa (ie, participants in the control group 
will receive the information about their level of advanced 
blood vessel disease at 12 weeks). A personalised report 
with the individual results and 12- week change will be 
provided to all participants by mail within 3 months of 
the end of the RCT.
Patient and public involvement
The study involved consumer representatives (n=2) in all 
aspects of the study design providing input to the processes 
and assessments of this research project. The Consumer 
and Community Health Research Network, through 
The Consumer and Community Involvement Coordi-
nator (Mr Ben Horgan) based at Edith Cowan Univer-
sity, assisted our Involvement Strategy by supporting us to 
find the most appropriate consumers for this work. The 
consumers were women over the age of 65 years who have 
attended five meetings, including four visits to the Medical 
Research Foundation and one visit to the Bone Density 
Department, over the last 12 months, prior to the start of 
the study. The women contributed to the design of the 
study, the informational material (results letter, handouts 
and videos) which supported the intervention and gave 
feedback about the burden of the intervention from the 
patient’s perspective (including clinical assessments and 
online questionnaires). The two women from the commu-
nity involved in this research provided feedback on their 
own clinical results and contributed to the dissemination 
plan of the study by suggesting which information should 
be provided and how it should be presented (graphic 
representation of scan results, providing feedback on the 
wording of all documents and questionnaires provided). 
The consumers were provided with a AU$30 gift card for 
each hour involved in the study. The information sheet 
for the GPs was developed with feedback from five GPs at 
two busy Perth Medical Clinics.
Outcome measures
Primary outcome measure
The primary outcome for this study will be circulating 
total serum carotenoid concentrations as biomarkers of 
FV intake.
Secondary outcomes
Secondary outcomes will affect changes on: (1) intake 
of FV assessed using a validated semiquantitative food 
frequency questionnaire (FFQ) developed by the Cancer 
Council of Victoria, Australia30 31; (2) adherence to 
other dietary recommendations including intake of 
wholegrains and saturated and trans fats, salt, sugar and 
alcohol assessed using the FFQ and other questionnaires; 
(3) physical activity (minutes of moderate to vigorous, 
number of steps per day, total minutes of physical activity, 
sitting time) assessed using accelerometers along with the 
Community Healthy Activities Model Program for Seniors 
(CHAMPS) questionnaire; (4) CVD risk factors (including 
lipids, blood glucose, blood pressure); (5) body weight 
and body composition (including total body and regional 
fat mass (kg) and body fat percentage, visceral adiposity 
(kg), lean mass (kg) and bone mineral density of the hip 
and spine (g/cm2)); (6) physical function (GS, timed- up- 
and- go and gait speed); (7) health- related measures such 
as sleep, smoking habits and knowledge and perception 
of CVD; (8) oral nitrite and nitrate concentrations; (9) 
medication and healthcare use and (10) psychological 
measures (such as depression and anxiety disorders and 
QoL).
Sample size
The required sample size for this study is 200 partici-
pants (n=100 control group; n=100 intervention group). 
We expect a withdrawal rate of approximately 10% at 12 
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until the sample size of 200 is reached, which is esti-
mated to take approximately 11 months. This sample 
will provide 85% power, with a two- sided type 1 error rate 
of alpha=0.05, to detect a 0.43 mg/L (~25%) difference 
between control and intervention in total circulating 
carotenoids at 12 weeks. This is based on a conservative 
estimate of a SD of 1.0 mg/L.32 In addition, a sample size 
of 100 participants in the intervention group will also 
provide more than 80% power to detect a dose–response 
effect (related to severity of AAC).
Participant allocation
Participants will be randomly allocated to either the 
intervention or control group in a 1:1 ratio. ‘Based on 
previous studies,33 34 we developed the inclusion criteria 
in order to have at least 50% per group with evidence of 
AAC’. The sequence of allocation will be generated using 
Stata V.14 (StataCorp) and the user- written module called 
‘ralloc’.35 Randomised blocks of size 4 will be created, so 
that the randomisation is balanced at the completion of 
assignment for each block. The randomisation will also 
be stratified according to the age group (above or below 
70 years) and sex. Within each strata, a sequential treat-
ment code will be printed on paper in the order of treat-
ment assignments. When the next available subject has 
completed baseline assessments, an investigator who is 
not involved in performing the intervention, data collec-
tion or data analysis will check the first available randomi-
sation code in the sequence, reveal the treatment to be 
assigned (intervention or control) and assign an appro-
priate code (A or B) next to the participants’ name on 
a list of participants. Both the participant and the inves-
tigators responsible for the counselling session will be 
unblinded throughout the trial. However, the researchers 
performing the outcome assessments and data analysis 
will be blinded to the treatments received until the end of 
data analysis when the treatment codes will be revealed.
data collection, management and analysis
Study investigators will have access to the data collection 
forms and protocols using a secure shared drive. Partici-
pant information will be kept confidential with only the 
study investigators having access to the data. Data will 
be stored in password- protected databases accessible 
only by study investigators. Original backup files will be 
kept in a separate electronic folder. The research will be 
conducted within a research facility with electronic and 
keycode access. All forms, protocols and questionnaires 
used will be compiled in files, for easy accessibility. Check-
lists for clinic preparation and clinic days will be used to 
ensure consistency. The following clinic assessments will 
be performed.
DXA scans and AAC scoring
DXA scans will be performed at Gairdner Bone Densi-
tometry Services, Sir Charles Gairdner Hospital, at the 
Perth site, using the latest fan beam technology (Hologic 
Horizon A densitometer). At the Deakin University site, 
DXA scans will be performed using the Lunar iDXA, GE 
Lunar, Madison, USA. The lateral spine image captured 
will allow for assessment of AAC. Bone density of the hip 
and spine as well as a whole body scans for body compo-
sition assessment will also be performed at the time of 
AAC measurement. Focal AAC will be scored using a 
semiquantitative scoring system (scored 0–24; AAC24). 
This involves assessing the linear length of the vascular 
calcification relative to the L1–L4 lumbar vertebra.34 36–39 
Briefly, the length of the calcifications on the anterior 
and posterior aortic walls is divided into four segments 
corresponding to the lumbar vertebrae 1–4. For both the 
anterior and posterior aortic walls, aortic calcification is 
scored 0 if there is no calcification present, 1 if ≤one- third 
of the aortic wall is calcified, 2 if >one- third to ≤two- thirds 
is calcified or 3 if >two- thirds is calcified. As such, calcifi-
cation corresponding to each of the four lumbar vertebra 
can achieve a maximum of 2×3=6 points with a combined 
maximum score of 24 points for L1–L4. All AAC scans will 
be analysed by experts in densitometric imaging (John 
Schousboe, University of Minnesota and/or Pawel Szulc, 
University of Lyon—France). The actual participant’s 
scan and pictorial representation of the presence and 
extent of the AAC will be provided to the intervention 
group at baseline and the control group at 12 weeks. The 
whole- body DXA scan will be used to measure fat mass, 
lean mass and visceral adipose tissue (VAT) mass. A tech-
nique for estimating VAT using DXA involves selecting 
an area of interest with the superior border at the cranial 
border of L2 and the inferior border at the caudal border 
of L4. This has been shown to be well correlated with 
CT- derived and MRI- derived measures of VAT (r2 >0.9).40
Anthropometry
Body weight will be measured using digital scales to 
the nearest 0.1 kg with participants wearing lightweight 
clothes and not wearing shoes. Height will be measured 
using a wall- mounted stadiometer to the nearest 0.1 cm 
while participants are not wearing shoes. BMI (kg/m2) 
will then be calculated as weight in kilogram, divided 
by height in metres squared. Waist circumference (cm) 
will be measured using a Cescorf steel measuring tape, 
in the standing position at the narrowest area between 
the lateral lower rib and the iliac crest.41 Hip measure-
ment (cm) will be taken at the largest circumference of 
the lower abdomen. Waist and hip circumferences will be 
measured three times and the median of each reported 
as the score.
Human specimens (blood, urine and saliva)
Blood samples will be collected and standard biochem-
ical analyses of fasting serum total cholesterol, HDL- 
cholesterol and triglycerides will be performed. 
Low- density lipoprotein cholesterol concentrations will 
be calculated using the Friedewald formula.42 Glucose 
and creatinine (eGFR) levels will be used to screen for 
presence of diabetes and determine kidney function. 
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using circulating serum carotenoid concentrations. High- 
performance liquid chromatography methodology will 
be used to determine serum carotenoid concentrations of 
β-carotene, lycopene, α-carotene, β-cryptoxanthin, lutein 
and zeaxanthin, as previously described.32 43 Serum carot-
enoids will be measured to assess FV intake, as FV are the 
primary contributors to intake of carotenoids (such as α- 
carotene, β-carotene and lutein/zeaxanthin)44 and they 
are recognised and commonly used biomarkers of FV 
consumption.45 A 24- hour urine sample will be collected 
in a sterile container provided. Urine samples will be 
analysed for electrolytes including creatinine, sodium 
and potassium. Saliva samples will be obtained to assess 
salivary nitrate and nitrite concentrations and to deter-
mine the nitrate to nitrite reduction ratio.46 Participants 
will be asked to sit quietly for 5 min while spitting into a 
sterile specimen container. Saliva aliquots will be stored 
at −80°C.
Clinic BP
Clinic BP will be assessed using a validated automatic 
BP monitor. After participants have rested for 5 min in a 
supine position, BP measurements will be assessed on five 
occasions at 1 min intervals. The first measurement will 
be discarded and the mean of the final four readings will 
be calculated.
Pulse wave analysis
PWA will be used to assess central aortic blood pressure 
and stiffness (augmentation index, %),47 using the Sphyg-
mocor Xcel device as described previously.48
Actigraphy
Accelerometry (ActiGraph GT3X, Pensacola, Florida, 
USA) will be used at baseline (lead- in- phase) and 12 
weeks, each for 7 consecutive days to investigate average 
daily physical activity levels. Of note, the ActiGraph 
device is the most widely used accelerometer in physical 
activity research.49 Briefly, participants will be instructed 
to wear the accelerometer over the right hip secured with 
an elastic band while awake and during sleep (if possible) 
and to remove the accelerometer when doing water activ-
ities. Accelerometers are ideal for determining physical 
activity as they require minimal input from the partici-
pant over the collection period. To improve the accuracy 
of our data, participants will also be asked to report any 
times the monitor is removed using a concurrent daily 
Activity Monitor Record/Nap Time Questionnaire during 
the 7- day period. Physical activity outcome measures will 
include moderate- to- vigorous physical activity (min/day), 
total physical activity (min/day), sedentary time (min/
day) and daily step count (steps/day). These measures 
will be quantified using the ActiLife Data Analysis Soft-
ware provided by the manufacturer (ActiLife V.6.13.4, 
Pensacola, Florida, USA).
Muscle strength and physical function
Muscle strength and physical function will be assessed by 
three tests: (1) GS of both the dominant and non- dominant 
hand will be recorded as the highest of three attempts50 
using a handheld dynamometer (Jamar Hydraulic Hand 
Grip Dynamometer; Nottinghamshire, UK); (2) timed 
up- and- go will be used to assess mobility, in which partici-
pants are timed (using a stopwatch) raising from a seated 
position on a standard arm chair (45 cm) and asked to 
walk at a comfortable and safe pace to a 3 m mark, turning 
to return to their seated position on the chair with their 
back touching the backrest of the chair.51 Participants will 
be instructed to perform one practice trial before the 
next two recorded attempts with the fastest time reported 
and (3) gait speed in which participants will be timed 
while walking at their usual pace over 4 m. Participants 
will be instructed to walk at their usual pace over 8 m and 
the time taken to walk the middle 4 m will be recorded on 
a stopwatch to determine gait speed. Time taken to walk 
the first and last 2 m of the course is excluded due to the 
acceleration and deceleration phases, respectively.52
Questionnaires
Dietary intake will be assessed using a semiquantita-
tive FFQ developed by the Cancer Council of Victoria, 
Australia,31 administered by one of the study investigators 
at each clinic visit. A link for a series of questionnaires to 
be completed online, which have been used widely in clin-
ical research including by our team, will be sent to partic-
ipants at baseline and 12 weeks, as described below: (1) 
Demographic and Lifestyle Questionnaire: will be used 
to assess demographic and lifestyle information, smoking 
habits and knowledge and perception of CVD risk; (2) 
Beverages Questionnaire: a self- administered beverage 
questionnaire will be used to estimate the average daily 
or weekly intake of beverages across 12 types of drinks 
(tea, herbal tea, coffee, decaffeinated coffee, chocolate, 
fruit juice, soft drinks, diet drinks, dairy milk, non- dairy 
milk, fruit and/or vegetable smoothies and water) as well 
as alcohol intake (beer, red and white wine and spirits); 
(3) CHAMPS questionnaire: a self- reported measure of 
physical activity to estimate weekly (4 weeks timeframe) 
frequency of participation (types) and energy expen-
diture (intensity levels) of physical activities in older 
adults53; (4) Longitudinal Ageing Study Amsterdam ques-
tionnaire will be used to assess sedentary behaviour54; 
(5) well- being and QoL will be assessed by the Medical 
Outcome Study Short Form‐36 (SF‐36)55 and the Sub- 
optimal Health Status questionnaire (SHSQ-25) status.56 
SF36 includes eight domains of physical functioning, 
role‐physical, bodily pain, general health, vitality, social 
functioning, role‐emotional and mental health, which 
are combined to form two key domains—physical func-
tioning and mental health. SHSQ-25 is composed of 25 
items and includes five subscales: fatigue, the cardiovas-
cular system, the digestive tract, the immune system and 
mental status; (6) Depression Anxiety Stress Scales-21: 
is a self- report questionnaire designed to measure the 
negative sensitive conditions of depression, anxiety and 
stress; (7) Bowel Symptoms Questionnaire will be used 
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chart, a medical tool designed to assess stool consistency 
(types 1 and 2 indicate constipation, types 3 and 4 are 
the ‘ideal stools’ and types 5–7 suggest diarrhoea or bowel 
urgency)57; (8) Readiness to Change and Wellbeing 
Questionnaire is a behaviour modification questionnaire 
(developed by the WorkStrong program, University of 
California system wide program) which focuses on indi-
viduals’ readiness to change over seven different aspects: 
life satisfaction, energy, weight, exercise, nutrition, health 
and stress and mental health; (9) Pittsburgh Sleep Quality 
Index: a questionnaire used to measure the quality and 
patterns of sleep in older adults58; (10) current medica-
tion use: a comprehensive list of medications (which will 
be cross- checked with bottles/packets of tablets concom-
itantly) and; (11) Health Care Use Questionnaire: will 
be used to investigate any procedures or further medical 
tests requested by GPs as well as visits to healthcare 
professionals. Online questionnaires will be checked for 
completeness prior to each clinic visit and any missing 
questions will be completed at the clinic visit. The ‘Life’s 
simple 7’ metric from the American Heart Association 
will be used to assess participant’s ‘ideal’ cardiovascular 
health. This considers seven risk factors that people can 
improve through lifestyle changes: quit smoking, increase 
their physical activity, achieve a healthy weight, eat a 
healthy diet, reduce their blood glucose, control their 
cholesterol and manage their blood pressure.59
Other forms
Participants will be asked to complete a 24- hour urine 
record form along with the Flavonoids questionnaire, 
which will be used to estimate the consumption of foods 
and beverages rich in flavan-3- ols in the 24 hours prior to 
their visit. The number of serves consumed (0, 1, 2, 3 or 
4+) across 22 foods and beverages will be assessed.
A postcounselling health status questionnaire will 
be used to assess the participants’ perceptions and 
intentions towards CVD risk and to the study proposed 
changes, immediately after receiving information on 
CVD and diet and lifestyle (counselling visit). The 
questions aim to explore participants perceived suscep-
tibility and severity60 61 in relation to the heart disease 
video content. It also explores the response efficacy, self- 
efficacy and their intentions (Likert scale: 1=strongly 
disagree; 5=strongly agree) towards the three main study 
goals.
Data management
The majority of data will be electronic and directly sent 
to the Qualtrics database. Online questionnaires have 
been designed with mandatory answers required to avoid 
missing data. Nevertheless, these data will be checked by 
an investigator prior to clinic day. Data from clinic assess-
ments and paper questionnaires will be entered into 
individual spreadsheets by a study investigator. A repre-
sentative number of files will be selected by a different 
investigator, who will check whether the information 
matches that in the electronic spreadsheets.
Statistical methods
Statistical analysis will be performed using IBM SPSS 
(V.25; IBM)62 and Stata V.14 (StataCorp). Descriptive 
statistics will be used to describe the individuals char-
acteristics at baseline. The primary analysis will be 
performed on a modified intention- to- treat basis with 
the population defined as those randomised participants 
for whom there are baseline measurements. Data will 
be assessed for outliers and normality prior to analysis 
and log- transformed if necessary. Baseline and 12- week 
values for outcome measures and between- group differ-
ences will be presented as means and SDs. The treatment 
effect for each of the outcomes will be analysed using 
generalised linear mixed models to examine the baseline 
adjusted differences between intervention and control in 
12- week values. In addition to including visit and treat-
ment group as fixed effects in each model, an interaction 
term between visit and treatment groups will be included 
and used to determine the effect of the intervention. 
The randomisation site and the individual will both be 
included in the models as random effects to account for 
clustering. A per- protocol analysis will be performed as 
a secondary analysis using only those participants with 
measures recorded at baseline and 12 weeks. An overall 
two- sided type-1 error rate of p<0.05 will be used to assess 
statistical significance for all hypothesis testing.
Monitoring
Participants will be monitored for any adverse events 
during clinical assessments by the study investigators 
which have been detailed in the participant informa-
tion form. The study clinical coordinator will oversee all 
aspects of participant management where required.
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Ethics approval for this study has been granted by the Edith 
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